Akerna Corp. (KERN) Stock Competitors & Peer Comparison
See (KERN) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| KERN | $0.31 | +36.94% | 162.3K | -0.01 | -$44.60 | N/A |
| BTSGU | $202.15 | +3.78% | 39B | N/A | N/A | N/A |
| VEEV | $178.66 | -2.34% | 29.1B | 32.87 | $5.43 | N/A |
| GEHC | $62.03 | +0.06% | 28.2B | 14.88 | $4.17 | +0.23% |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | N/A |
| BTSG | $60.88 | +2.60% | 11.8B | 79.06 | $0.77 | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| TEM | $47.51 | -4.25% | 8.3B | -27.62 | -$1.72 | N/A |
| HQY | $85.21 | -3.54% | 7.1B | 31.91 | $2.67 | N/A |
| RCM | $14.31 | N/A | 6B | -102.21 | -$0.14 | N/A |
Stock Comparison
KERN vs BTSGU Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, BTSGU has a market cap of 39B. Regarding current trading prices, KERN is priced at $0.31, while BTSGU trades at $202.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas BTSGU's P/E ratio is N/A. In terms of profitability, KERN's ROE is -0.17%, compared to BTSGU's ROE of +0.13%. Regarding short-term risk, KERN is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check BTSGU's competition here
KERN vs VEEV Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, VEEV has a market cap of 29.1B. Regarding current trading prices, KERN is priced at $0.31, while VEEV trades at $178.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas VEEV's P/E ratio is 32.87. In terms of profitability, KERN's ROE is -0.17%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, KERN is more volatile compared to VEEV. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check VEEV's competition here
KERN vs GEHC Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, GEHC has a market cap of 28.2B. Regarding current trading prices, KERN is priced at $0.31, while GEHC trades at $62.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas GEHC's P/E ratio is 14.88. In terms of profitability, KERN's ROE is -0.17%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, KERN is more volatile compared to GEHC. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check GEHC's competition here
KERN vs GEHCV Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, KERN is priced at $0.31, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas GEHCV's P/E ratio is N/A. In terms of profitability, KERN's ROE is -0.17%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, KERN is more volatile compared to GEHCV. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check GEHCV's competition here
KERN vs BTSG Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, BTSG has a market cap of 11.8B. Regarding current trading prices, KERN is priced at $0.31, while BTSG trades at $60.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas BTSG's P/E ratio is 79.06. In terms of profitability, KERN's ROE is -0.17%, compared to BTSG's ROE of +0.13%. Regarding short-term risk, KERN is more volatile compared to BTSG. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check BTSG's competition here
KERN vs SGFY Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, KERN is priced at $0.31, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SGFY's P/E ratio is 70.91. In terms of profitability, KERN's ROE is -0.17%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, KERN is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check SGFY's competition here
KERN vs TEM Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, TEM has a market cap of 8.3B. Regarding current trading prices, KERN is priced at $0.31, while TEM trades at $47.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas TEM's P/E ratio is -27.62. In terms of profitability, KERN's ROE is -0.17%, compared to TEM's ROE of -0.70%. Regarding short-term risk, KERN is more volatile compared to TEM. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check TEM's competition here
KERN vs HQY Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, HQY has a market cap of 7.1B. Regarding current trading prices, KERN is priced at $0.31, while HQY trades at $85.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas HQY's P/E ratio is 31.91. In terms of profitability, KERN's ROE is -0.17%, compared to HQY's ROE of +0.11%. Regarding short-term risk, KERN is more volatile compared to HQY. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check HQY's competition here
KERN vs RCM Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, RCM has a market cap of 6B. Regarding current trading prices, KERN is priced at $0.31, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas RCM's P/E ratio is -102.21. In terms of profitability, KERN's ROE is -0.17%, compared to RCM's ROE of +0.00%. Regarding short-term risk, KERN is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check RCM's competition here
KERN vs HNGE Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, HNGE has a market cap of 4.5B. Regarding current trading prices, KERN is priced at $0.31, while HNGE trades at $58.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas HNGE's P/E ratio is -6.59. In terms of profitability, KERN's ROE is -0.17%, compared to HNGE's ROE of -1.39%. Regarding short-term risk, KERN is more volatile compared to HNGE. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check HNGE's competition here
KERN vs TXG Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, TXG has a market cap of 4.1B. Regarding current trading prices, KERN is priced at $0.31, while TXG trades at $32.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas TXG's P/E ratio is -189.18. In terms of profitability, KERN's ROE is -0.17%, compared to TXG's ROE of -0.03%. Regarding short-term risk, KERN is more volatile compared to TXG. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check TXG's competition here
KERN vs DOCS Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, DOCS has a market cap of 3.9B. Regarding current trading prices, KERN is priced at $0.31, while DOCS trades at $21.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas DOCS's P/E ratio is 21.47. In terms of profitability, KERN's ROE is -0.17%, compared to DOCS's ROE of +0.19%. Regarding short-term risk, KERN is more volatile compared to DOCS. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check DOCS's competition here
KERN vs ONEM Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, KERN is priced at $0.31, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas ONEM's P/E ratio is -7.77. In terms of profitability, KERN's ROE is -0.17%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, KERN is more volatile compared to ONEM. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check ONEM's competition here
KERN vs PRVA Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, PRVA has a market cap of 2.6B. Regarding current trading prices, KERN is priced at $0.31, while PRVA trades at $20.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas PRVA's P/E ratio is 121.53. In terms of profitability, KERN's ROE is -0.17%, compared to PRVA's ROE of +0.03%. Regarding short-term risk, KERN is more volatile compared to PRVA. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check PRVA's competition here
KERN vs HTFL Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, HTFL has a market cap of 2.5B. Regarding current trading prices, KERN is priced at $0.31, while HTFL trades at $28.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas HTFL's P/E ratio is -9.34. In terms of profitability, KERN's ROE is -0.17%, compared to HTFL's ROE of +8.30%. Regarding short-term risk, KERN is more volatile compared to HTFL. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check HTFL's competition here
KERN vs PINC Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, PINC has a market cap of 2.3B. Regarding current trading prices, KERN is priced at $0.31, while PINC trades at $28.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas PINC's P/E ratio is 166.24. In terms of profitability, KERN's ROE is -0.17%, compared to PINC's ROE of -0.02%. Regarding short-term risk, KERN is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check PINC's competition here
KERN vs PGNY Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, PGNY has a market cap of 2B. Regarding current trading prices, KERN is priced at $0.31, while PGNY trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas PGNY's P/E ratio is 32.46. In terms of profitability, KERN's ROE is -0.17%, compared to PGNY's ROE of +0.13%. Regarding short-term risk, KERN is more volatile compared to PGNY. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check PGNY's competition here
KERN vs OMCL Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, OMCL has a market cap of 1.9B. Regarding current trading prices, KERN is priced at $0.31, while OMCL trades at $41.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas OMCL's P/E ratio is 95.20. In terms of profitability, KERN's ROE is -0.17%, compared to OMCL's ROE of +0.02%. Regarding short-term risk, KERN is more volatile compared to OMCL. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check OMCL's competition here
KERN vs NXGN Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, KERN is priced at $0.31, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas NXGN's P/E ratio is -266.00. In terms of profitability, KERN's ROE is -0.17%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, KERN is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check NXGN's competition here
KERN vs WGS Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, WGS has a market cap of 1.6B. Regarding current trading prices, KERN is priced at $0.31, while WGS trades at $53.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas WGS's P/E ratio is -19.93. In terms of profitability, KERN's ROE is -0.17%, compared to WGS's ROE of -0.28%. Regarding short-term risk, KERN is more volatile compared to WGS. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check WGS's competition here
KERN vs AGTI Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, KERN is priced at $0.31, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas AGTI's P/E ratio is -71.79. In terms of profitability, KERN's ROE is -0.17%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, KERN is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check AGTI's competition here
KERN vs TDOC Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, TDOC has a market cap of 1.3B. Regarding current trading prices, KERN is priced at $0.31, while TDOC trades at $7.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas TDOC's P/E ratio is -7.30. In terms of profitability, KERN's ROE is -0.17%, compared to TDOC's ROE of -0.12%. Regarding short-term risk, KERN is more volatile compared to TDOC. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check TDOC's competition here
KERN vs SDGR Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SDGR has a market cap of 1.1B. Regarding current trading prices, KERN is priced at $0.31, while SDGR trades at $14.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SDGR's P/E ratio is -10.66. In terms of profitability, KERN's ROE is -0.17%, compared to SDGR's ROE of -0.31%. Regarding short-term risk, KERN is more volatile compared to SDGR. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check SDGR's competition here
KERN vs OMDA Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, OMDA has a market cap of 1B. Regarding current trading prices, KERN is priced at $0.31, while OMDA trades at $17.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas OMDA's P/E ratio is -75.35. In terms of profitability, KERN's ROE is -0.17%, compared to OMDA's ROE of -0.03%. Regarding short-term risk, KERN is more volatile compared to OMDA. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check OMDA's competition here
KERN vs GDRX Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, GDRX has a market cap of 974M. Regarding current trading prices, KERN is priced at $0.31, while GDRX trades at $2.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas GDRX's P/E ratio is 46.83. In terms of profitability, KERN's ROE is -0.17%, compared to GDRX's ROE of +0.03%. Regarding short-term risk, KERN is more volatile compared to GDRX. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check GDRX's competition here
KERN vs CERT Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, CERT has a market cap of 871.2M. Regarding current trading prices, KERN is priced at $0.31, while CERT trades at $5.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas CERT's P/E ratio is -56.00. In terms of profitability, KERN's ROE is -0.17%, compared to CERT's ROE of -0.01%. Regarding short-term risk, KERN is more volatile compared to CERT. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check CERT's competition here
KERN vs CCLDO Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, KERN is priced at $0.31, while CCLDO trades at $27.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas CCLDO's P/E ratio is N/A. In terms of profitability, KERN's ROE is -0.17%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, KERN is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check CCLDO's competition here
KERN vs NUTX Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, NUTX has a market cap of 790.9M. Regarding current trading prices, KERN is priced at $0.31, while NUTX trades at $132.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas NUTX's P/E ratio is 9.72. In terms of profitability, KERN's ROE is -0.17%, compared to NUTX's ROE of +0.31%. Regarding short-term risk, KERN is more volatile compared to NUTX. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check NUTX's competition here
KERN vs HSTM Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, HSTM has a market cap of 716.9M. Regarding current trading prices, KERN is priced at $0.31, while HSTM trades at $24.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas HSTM's P/E ratio is 36.63. In terms of profitability, KERN's ROE is -0.17%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, KERN is more volatile compared to HSTM. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check HSTM's competition here
KERN vs MPLN-WT Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, KERN is priced at $0.31, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, KERN's ROE is -0.17%, compared to MPLN-WT's ROE of +2.06%. Regarding short-term risk, KERN is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.Check MPLN-WT's competition here
KERN vs PHR Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, PHR has a market cap of 596.2M. Regarding current trading prices, KERN is priced at $0.31, while PHR trades at $9.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas PHR's P/E ratio is 60.28. In terms of profitability, KERN's ROE is -0.17%, compared to PHR's ROE of +0.03%. Regarding short-term risk, KERN is more volatile compared to PHR. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check PHR's competition here
KERN vs ACCD Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, KERN is priced at $0.31, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas ACCD's P/E ratio is -3.08. In terms of profitability, KERN's ROE is -0.17%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, KERN is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check ACCD's competition here
KERN vs SHCR Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, KERN is priced at $0.31, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SHCR's P/E ratio is -3.76. In terms of profitability, KERN's ROE is -0.17%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, KERN is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check SHCR's competition here
KERN vs CTEV Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, CTEV has a market cap of 448.4M. Regarding current trading prices, KERN is priced at $0.31, while CTEV trades at $26.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas CTEV's P/E ratio is -1.52. In terms of profitability, KERN's ROE is -0.17%, compared to CTEV's ROE of +2.06%. Regarding short-term risk, KERN is more volatile compared to CTEV. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check CTEV's competition here
KERN vs NRC Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, NRC has a market cap of 429.1M. Regarding current trading prices, KERN is priced at $0.31, while NRC trades at $19.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas NRC's P/E ratio is 45.33. In terms of profitability, KERN's ROE is -0.17%, compared to NRC's ROE of +0.57%. Regarding short-term risk, KERN is more volatile compared to NRC. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check NRC's competition here
KERN vs EVH Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, EVH has a market cap of 424.6M. Regarding current trading prices, KERN is priced at $0.31, while EVH trades at $3.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas EVH's P/E ratio is -0.81. In terms of profitability, KERN's ROE is -0.17%, compared to EVH's ROE of -0.78%. Regarding short-term risk, KERN is more volatile compared to EVH. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check EVH's competition here
KERN vs SLGCW Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, KERN is priced at $0.31, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, KERN's ROE is -0.17%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, KERN is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.Check SLGCW's competition here
KERN vs SLGC Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, KERN is priced at $0.31, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SLGC's P/E ratio is -3.04. In terms of profitability, KERN's ROE is -0.17%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, KERN is more volatile compared to SLGC. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check SLGC's competition here
KERN vs TBRG Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, TBRG has a market cap of 389.5M. Regarding current trading prices, KERN is priced at $0.31, while TBRG trades at $25.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas TBRG's P/E ratio is 89.55. In terms of profitability, KERN's ROE is -0.17%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, KERN is more volatile compared to TBRG. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check TBRG's competition here
KERN vs MPLN Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, KERN is priced at $0.31, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas MPLN's P/E ratio is -0.23. In terms of profitability, KERN's ROE is -0.17%, compared to MPLN's ROE of +2.06%. Regarding short-term risk, KERN is more volatile compared to MPLN. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check MPLN's competition here
KERN vs SOPH Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SOPH has a market cap of 342.6M. Regarding current trading prices, KERN is priced at $0.31, while SOPH trades at $4.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SOPH's P/E ratio is -4.05. In terms of profitability, KERN's ROE is -0.17%, compared to SOPH's ROE of -1.41%. Regarding short-term risk, KERN is more volatile compared to SOPH. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check SOPH's competition here
KERN vs SLP Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SLP has a market cap of 326.7M. Regarding current trading prices, KERN is priced at $0.31, while SLP trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SLP's P/E ratio is -5.18. In terms of profitability, KERN's ROE is -0.17%, compared to SLP's ROE of -0.49%. Regarding short-term risk, KERN is more volatile compared to SLP. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check SLP's competition here
KERN vs TRHC Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, KERN is priced at $0.31, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas TRHC's P/E ratio is -4.27. In terms of profitability, KERN's ROE is -0.17%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, KERN is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check TRHC's competition here
KERN vs CARL Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, CARL has a market cap of 277.3M. Regarding current trading prices, KERN is priced at $0.31, while CARL trades at $10.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas CARL's P/E ratio is -10.41. In terms of profitability, KERN's ROE is -0.17%, compared to CARL's ROE of -0.62%. Regarding short-term risk, KERN is more volatile compared to CARL. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check CARL's competition here
KERN vs SY Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SY has a market cap of 255.9M. Regarding current trading prices, KERN is priced at $0.31, while SY trades at $1.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SY's P/E ratio is -5.13. In terms of profitability, KERN's ROE is -0.17%, compared to SY's ROE of -0.16%. Regarding short-term risk, KERN is more volatile compared to SY. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check SY's competition here
KERN vs SMFR Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, KERN is priced at $0.31, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SMFR's P/E ratio is N/A. In terms of profitability, KERN's ROE is -0.17%, compared to SMFR's ROE of -0.28%. Regarding short-term risk, KERN is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.Check SMFR's competition here
KERN vs SPOK Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SPOK has a market cap of 221.2M. Regarding current trading prices, KERN is priced at $0.31, while SPOK trades at $10.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SPOK's P/E ratio is 17.95. In terms of profitability, KERN's ROE is -0.17%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, KERN is more volatile compared to SPOK. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check SPOK's competition here
KERN vs AMWL Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, AMWL has a market cap of 140.5M. Regarding current trading prices, KERN is priced at $0.31, while AMWL trades at $8.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas AMWL's P/E ratio is -1.55. In terms of profitability, KERN's ROE is -0.17%, compared to AMWL's ROE of -0.35%. Regarding short-term risk, KERN is more volatile compared to AMWL. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check AMWL's competition here
KERN vs CPSI Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, KERN is priced at $0.31, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas CPSI's P/E ratio is -183.80. In terms of profitability, KERN's ROE is -0.17%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, KERN is more volatile compared to CPSI. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check CPSI's competition here
KERN vs AUGX Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, KERN is priced at $0.31, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas AUGX's P/E ratio is -4.99. In terms of profitability, KERN's ROE is -0.17%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, KERN is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check AUGX's competition here
KERN vs CCLD Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, CCLD has a market cap of 99.9M. Regarding current trading prices, KERN is priced at $0.31, while CCLD trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas CCLD's P/E ratio is 18.08. In terms of profitability, KERN's ROE is -0.17%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, KERN is more volatile compared to CCLD. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check CCLD's competition here
KERN vs HCAT Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, HCAT has a market cap of 98.3M. Regarding current trading prices, KERN is priced at $0.31, while HCAT trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas HCAT's P/E ratio is -0.36. In terms of profitability, KERN's ROE is -0.17%, compared to HCAT's ROE of -1.00%. Regarding short-term risk, KERN is more volatile compared to HCAT. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check HCAT's competition here
KERN vs OPRX Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, OPRX has a market cap of 92.9M. Regarding current trading prices, KERN is priced at $0.31, while OPRX trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas OPRX's P/E ratio is 13.75. In terms of profitability, KERN's ROE is -0.17%, compared to OPRX's ROE of +0.05%. Regarding short-term risk, KERN is more volatile compared to OPRX. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check OPRX's competition here
KERN vs DH Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, DH has a market cap of 92.6M. Regarding current trading prices, KERN is priced at $0.31, while DH trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas DH's P/E ratio is -0.53. In terms of profitability, KERN's ROE is -0.17%, compared to DH's ROE of -0.67%. Regarding short-term risk, KERN is more volatile compared to DH. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check DH's competition here
KERN vs FORA Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, FORA has a market cap of 67.8M. Regarding current trading prices, KERN is priced at $0.31, while FORA trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas FORA's P/E ratio is -24.11. In terms of profitability, KERN's ROE is -0.17%, compared to FORA's ROE of -0.17%. Regarding short-term risk, KERN is more volatile compared to FORA. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check FORA's competition here
KERN vs CCLDP Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, KERN is priced at $0.31, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas CCLDP's P/E ratio is N/A. In terms of profitability, KERN's ROE is -0.17%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, KERN is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check CCLDP's competition here
KERN vs ONMD Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, ONMD has a market cap of 41.7M. Regarding current trading prices, KERN is priced at $0.31, while ONMD trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas ONMD's P/E ratio is -19.16. In terms of profitability, KERN's ROE is -0.17%, compared to ONMD's ROE of +0.90%. Regarding short-term risk, KERN is more volatile compared to ONMD. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check ONMD's competition here
KERN vs SNCE Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, KERN is priced at $0.31, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SNCE's P/E ratio is -0.27. In terms of profitability, KERN's ROE is -0.17%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, KERN is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check SNCE's competition here
KERN vs AKLI Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, KERN is priced at $0.31, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas AKLI's P/E ratio is -0.71. In terms of profitability, KERN's ROE is -0.17%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, KERN is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check AKLI's competition here
KERN vs SHLT Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, KERN is priced at $0.31, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SHLT's P/E ratio is -3.87. In terms of profitability, KERN's ROE is -0.17%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, KERN is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check SHLT's competition here
KERN vs SHCRW Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, KERN is priced at $0.31, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, KERN's ROE is -0.17%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, KERN is more volatile compared to SHCRW. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check SHCRW's competition here
KERN vs EUDA Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, EUDA has a market cap of 31.1M. Regarding current trading prices, KERN is priced at $0.31, while EUDA trades at $16.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas EUDA's P/E ratio is -11.24. In terms of profitability, KERN's ROE is -0.17%, compared to EUDA's ROE of +0.13%. Regarding short-term risk, KERN is more volatile compared to EUDA. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check EUDA's competition here
KERN vs BEAT Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, BEAT has a market cap of 30.7M. Regarding current trading prices, KERN is priced at $0.31, while BEAT trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas BEAT's P/E ratio is -1.59. In terms of profitability, KERN's ROE is -0.17%, compared to BEAT's ROE of -10.34%. Regarding short-term risk, KERN is more volatile compared to BEAT. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check BEAT's competition here
KERN vs ONMDW Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, ONMDW has a market cap of 30.4M. Regarding current trading prices, KERN is priced at $0.31, while ONMDW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas ONMDW's P/E ratio is N/A. In terms of profitability, KERN's ROE is -0.17%, compared to ONMDW's ROE of +0.90%. Regarding short-term risk, KERN is more volatile compared to ONMDW. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check ONMDW's competition here
KERN vs STRM Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, KERN is priced at $0.31, while STRM trades at $5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas STRM's P/E ratio is -2.40. In terms of profitability, KERN's ROE is -0.17%, compared to STRM's ROE of -0.32%. Regarding short-term risk, KERN is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check STRM's competition here
KERN vs RNLX Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, KERN is priced at $0.31, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas RNLX's P/E ratio is -0.33. In terms of profitability, KERN's ROE is -0.17%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, KERN is more volatile compared to RNLX. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check RNLX's competition here
KERN vs LIFW Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, KERN is priced at $0.31, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas LIFW's P/E ratio is -0.02. In terms of profitability, KERN's ROE is -0.17%, compared to LIFW's ROE of +3.93%. Regarding short-term risk, KERN is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check LIFW's competition here
KERN vs BBLN Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, KERN is priced at $0.31, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas BBLN's P/E ratio is -0.04. In terms of profitability, KERN's ROE is -0.17%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, KERN is more volatile compared to BBLN. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check BBLN's competition here
KERN vs ETAO Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, KERN is priced at $0.31, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas ETAO's P/E ratio is -0.01. In terms of profitability, KERN's ROE is -0.17%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, KERN is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.Check ETAO's competition here
KERN vs BFRG Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, BFRG has a market cap of 7.7M. Regarding current trading prices, KERN is priced at $0.31, while BFRG trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas BFRG's P/E ratio is -1.35. In terms of profitability, KERN's ROE is -0.17%, compared to BFRG's ROE of -2.18%. Regarding short-term risk, KERN is more volatile compared to BFRG. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check BFRG's competition here
KERN vs HLTH Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, KERN is priced at $0.31, while HLTH trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas HLTH's P/E ratio is -0.02. In terms of profitability, KERN's ROE is -0.17%, compared to HLTH's ROE of -0.90%. Regarding short-term risk, KERN is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.Check HLTH's competition here
KERN vs SCNX Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SCNX has a market cap of 5.7M. Regarding current trading prices, KERN is priced at $0.31, while SCNX trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SCNX's P/E ratio is -0.15. In terms of profitability, KERN's ROE is -0.17%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, KERN is more volatile compared to SCNX. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check SCNX's competition here
KERN vs UPH-WT Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, KERN is priced at $0.31, while UPH-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, KERN's ROE is -0.17%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, KERN is less volatile compared to UPH-WT. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.Check UPH-WT's competition here
KERN vs UPH Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, KERN is priced at $0.31, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas UPH's P/E ratio is -0.07. In terms of profitability, KERN's ROE is -0.17%, compared to UPH's ROE of -1.05%. Regarding short-term risk, KERN is more volatile compared to UPH. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check UPH's competition here
KERN vs PEAR Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, KERN is priced at $0.31, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas PEAR's P/E ratio is -0.08. In terms of profitability, KERN's ROE is -0.17%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, KERN is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.Check PEAR's competition here
KERN vs PEARW Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, KERN is priced at $0.31, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas PEARW's P/E ratio is -0.00. In terms of profitability, KERN's ROE is -0.17%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, KERN is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.Check PEARW's competition here
KERN vs MGRX Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, MGRX has a market cap of 3.8M. Regarding current trading prices, KERN is priced at $0.31, while MGRX trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas MGRX's P/E ratio is -0.30. In terms of profitability, KERN's ROE is -0.17%, compared to MGRX's ROE of -1.21%. Regarding short-term risk, KERN is more volatile compared to MGRX. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check MGRX's competition here
KERN vs HCTI Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, HCTI has a market cap of 2.7M. Regarding current trading prices, KERN is priced at $0.31, while HCTI trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas HCTI's P/E ratio is 0.01. In terms of profitability, KERN's ROE is -0.17%, compared to HCTI's ROE of -0.68%. Regarding short-term risk, KERN is more volatile compared to HCTI. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check HCTI's competition here
KERN vs BEATW Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, BEATW has a market cap of 2.7M. Regarding current trading prices, KERN is priced at $0.31, while BEATW trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas BEATW's P/E ratio is -0.16. In terms of profitability, KERN's ROE is -0.17%, compared to BEATW's ROE of -10.34%. Regarding short-term risk, KERN is less volatile compared to BEATW. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.Check BEATW's competition here
KERN vs VSEE Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, VSEE has a market cap of 2.6M. Regarding current trading prices, KERN is priced at $0.31, while VSEE trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas VSEE's P/E ratio is -0.30. In terms of profitability, KERN's ROE is -0.17%, compared to VSEE's ROE of -115.71%. Regarding short-term risk, KERN is more volatile compared to VSEE. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check VSEE's competition here
KERN vs OTRK Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, KERN is priced at $0.31, while OTRK trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas OTRK's P/E ratio is -0.02. In terms of profitability, KERN's ROE is -0.17%, compared to OTRK's ROE of -1.66%. Regarding short-term risk, KERN is more volatile compared to OTRK. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check OTRK's competition here
KERN vs BFRGW Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, BFRGW has a market cap of 2.2M. Regarding current trading prices, KERN is priced at $0.31, while BFRGW trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas BFRGW's P/E ratio is N/A. In terms of profitability, KERN's ROE is -0.17%, compared to BFRGW's ROE of -2.18%. Regarding short-term risk, KERN is less volatile compared to BFRGW. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.Check BFRGW's competition here
KERN vs ACON Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, ACON has a market cap of 1.9M. Regarding current trading prices, KERN is priced at $0.31, while ACON trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas ACON's P/E ratio is -0.62. In terms of profitability, KERN's ROE is -0.17%, compared to ACON's ROE of -0.54%. Regarding short-term risk, KERN is more volatile compared to ACON. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check ACON's competition here
KERN vs CMAX Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, KERN is priced at $0.31, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas CMAX's P/E ratio is -0.00. In terms of profitability, KERN's ROE is -0.17%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, KERN is more volatile compared to CMAX. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check CMAX's competition here
KERN vs LIFWZ Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, KERN is priced at $0.31, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, KERN's ROE is -0.17%, compared to LIFWZ's ROE of +3.93%. Regarding short-term risk, KERN is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check LIFWZ's competition here
KERN vs VSEEW Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, VSEEW has a market cap of 1M. Regarding current trading prices, KERN is priced at $0.31, while VSEEW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas VSEEW's P/E ratio is N/A. In terms of profitability, KERN's ROE is -0.17%, compared to VSEEW's ROE of -115.71%. Regarding short-term risk, KERN is more volatile compared to VSEEW. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check VSEEW's competition here
KERN vs EUDAW Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, EUDAW has a market cap of 990.6K. Regarding current trading prices, KERN is priced at $0.31, while EUDAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas EUDAW's P/E ratio is N/A. In terms of profitability, KERN's ROE is -0.17%, compared to EUDAW's ROE of +0.13%. Regarding short-term risk, KERN is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.Check EUDAW's competition here
KERN vs MSPRZ Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, KERN is priced at $0.31, while MSPRZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, KERN's ROE is -0.17%, compared to MSPRZ's ROE of +3.93%. Regarding short-term risk, KERN is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.Check MSPRZ's competition here
KERN vs MSPR Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, MSPR has a market cap of 370.5K. Regarding current trading prices, KERN is priced at $0.31, while MSPR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas MSPR's P/E ratio is N/A. In terms of profitability, KERN's ROE is -0.17%, compared to MSPR's ROE of +3.93%. Regarding short-term risk, KERN is more volatile compared to MSPR. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check MSPR's competition here
KERN vs WORX Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, WORX has a market cap of 303.5K. Regarding current trading prices, KERN is priced at $0.31, while WORX trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas WORX's P/E ratio is -0.20. In terms of profitability, KERN's ROE is -0.17%, compared to WORX's ROE of -0.65%. Regarding short-term risk, KERN is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.Check WORX's competition here
KERN vs ZCMD Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, ZCMD has a market cap of 173.8K. Regarding current trading prices, KERN is priced at $0.31, while ZCMD trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas ZCMD's P/E ratio is -0.03. In terms of profitability, KERN's ROE is -0.17%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, KERN is less volatile compared to ZCMD. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.Check ZCMD's competition here
KERN vs WGSWW Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, WGSWW has a market cap of 170.7K. Regarding current trading prices, KERN is priced at $0.31, while WGSWW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas WGSWW's P/E ratio is N/A. In terms of profitability, KERN's ROE is -0.17%, compared to WGSWW's ROE of -0.28%. Regarding short-term risk, KERN is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.Check WGSWW's competition here
KERN vs KERNW Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, KERN is priced at $0.31, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas KERNW's P/E ratio is -0.00. In terms of profitability, KERN's ROE is -0.17%, compared to KERNW's ROE of -0.17%. Regarding short-term risk, KERN is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.Check KERNW's competition here
KERN vs LIFWW Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, KERN is priced at $0.31, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas LIFWW's P/E ratio is N/A. In terms of profitability, KERN's ROE is -0.17%, compared to LIFWW's ROE of +3.93%. Regarding short-term risk, KERN is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check LIFWW's competition here
KERN vs OTRKP Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, OTRKP has a market cap of 50.1K. Regarding current trading prices, KERN is priced at $0.31, while OTRKP trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas OTRKP's P/E ratio is -0.00. In terms of profitability, KERN's ROE is -0.17%, compared to OTRKP's ROE of -1.66%. Regarding short-term risk, KERN is less volatile compared to OTRKP. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.Check OTRKP's competition here
KERN vs CMAXW Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, KERN is priced at $0.31, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas CMAXW's P/E ratio is N/A. In terms of profitability, KERN's ROE is -0.17%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, KERN is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check CMAXW's competition here
KERN vs ACONW Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, ACONW has a market cap of 15.7K. Regarding current trading prices, KERN is priced at $0.31, while ACONW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas ACONW's P/E ratio is N/A. In terms of profitability, KERN's ROE is -0.17%, compared to ACONW's ROE of -0.54%. Regarding short-term risk, KERN is less volatile compared to ACONW. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.Check ACONW's competition here
KERN vs ICCT Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, ICCT has a market cap of 5.4K. Regarding current trading prices, KERN is priced at $0.31, while ICCT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas ICCT's P/E ratio is N/A. In terms of profitability, KERN's ROE is -0.17%, compared to ICCT's ROE of +11.65%. Regarding short-term risk, KERN is more volatile compared to ICCT. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check ICCT's competition here
KERN vs FOXO Comparison June 2026
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, FOXO has a market cap of 3K. Regarding current trading prices, KERN is priced at $0.31, while FOXO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas FOXO's P/E ratio is N/A. In terms of profitability, KERN's ROE is -0.17%, compared to FOXO's ROE of -0.97%. Regarding short-term risk, KERN is more volatile compared to FOXO. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.Check FOXO's competition here